| pubmed-article:21569025 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21569025 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21569025 | lifeskim:mentions | umls-concept:C0751122 | lld:lifeskim |
| pubmed-article:21569025 | lifeskim:mentions | umls-concept:C0259972 | lld:lifeskim |
| pubmed-article:21569025 | lifeskim:mentions | umls-concept:C0075262 | lld:lifeskim |
| pubmed-article:21569025 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:21569025 | lifeskim:mentions | umls-concept:C0814225 | lld:lifeskim |
| pubmed-article:21569025 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:21569025 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:21569025 | pubmed:dateCreated | 2011-7-6 | lld:pubmed |
| pubmed-article:21569025 | pubmed:abstractText | We aimed to test the efficacy of ketogenic diet (KD) in patients with Dravet syndrome (DS) not satisfactorily controlled by antiepileptic drugs (AEDs). We included prospectively 15 DS patients aged >3 years with partial response to AEDs including stiripentol. All patients had a seizure diary and clinical examination with Conners and Achenbach scales before KD, at 1 month following onset and every 3 months thereafter. At 1 month, 10 patients (66%) had a decrease of seizure frequency ?75%. Efficacy was maintained in eight responders at 3 and 6 months and in six responders at 9 months. Five patients (33%) remained on KD over 12 months, and one was seizure-free. In addition to efficacy on seizure frequency, KD was beneficial on behavior disturbances including hyperactivity. This effect was reported in all responders and in a few nonresponders. KD might have a double effect, on seizure control and on hyperactivity and behavior disturbances in patients with DS. | lld:pubmed |
| pubmed-article:21569025 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21569025 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21569025 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21569025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21569025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21569025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21569025 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21569025 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:21569025 | pubmed:issn | 1528-1167 | lld:pubmed |
| pubmed-article:21569025 | pubmed:author | pubmed-author:DulacOlivierO | lld:pubmed |
| pubmed-article:21569025 | pubmed:author | pubmed-author:ChironCatheri... | lld:pubmed |
| pubmed-article:21569025 | pubmed:author | pubmed-author:NabboutRimaR | lld:pubmed |
| pubmed-article:21569025 | pubmed:author | pubmed-author:DesguerreIsab... | lld:pubmed |
| pubmed-article:21569025 | pubmed:author | pubmed-author:CopioliCristi... | lld:pubmed |
| pubmed-article:21569025 | pubmed:author | pubmed-author:ChipauxMathil... | lld:pubmed |
| pubmed-article:21569025 | pubmed:author | pubmed-author:ChemalyNicole... | lld:pubmed |
| pubmed-article:21569025 | pubmed:copyrightInfo | Wiley Periodicals, Inc. © 2011 International League Against Epilepsy. | lld:pubmed |
| pubmed-article:21569025 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21569025 | pubmed:volume | 52 | lld:pubmed |
| pubmed-article:21569025 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21569025 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21569025 | pubmed:pagination | e54-7 | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:meshHeading | pubmed-meshheading:21569025... | lld:pubmed |
| pubmed-article:21569025 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21569025 | pubmed:articleTitle | Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. | lld:pubmed |
| pubmed-article:21569025 | pubmed:affiliation | Department of Neuropediatrics, National Referral Center for Rare Epilepsies, Necker-Enfants Malades Hospital, 149 rue de Sévres, Paris, France. rimanabbout@yahoo.com | lld:pubmed |
| pubmed-article:21569025 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21569025 | pubmed:publicationType | Clinical Trial | lld:pubmed |
